Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

scientific article published in March 2018

Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/IBD/IZX105
P698PubMed publication ID29506124

P50authorAtsushi SakurabaQ51055396
P2093author name stringDavid T Rubin
Stephen B Hanauer
Russell D Cohen
Parita Patel
Sushila Dalal
Joel Pekow
Laura H Raffals
Andres Yarur
Ira Hanan
P2860cites workCiclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.Q53122367
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.Q54007642
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial manQ57265461
Preliminary report: cyclosporin in treatment of severe active ulcerative colitisQ68091416
Course of ulcerative colitis: analysis of changes in disease activity over yearsQ72036054
Cyclosporin for severe ulcerative colitis: a user's guideQ73747657
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitisQ80269736
[Use of infliximab in ulcerative colitis]Q80802092
Management of acute, severe ulcerative colitisQ83275256
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I studyQ84794233
Infliximab for induction and maintenance therapy for ulcerative colitisQ28285876
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort studyQ33280166
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitisQ34009451
Cyclosporine in severe ulcerative colitis refractory to steroid therapyQ34060783
MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE.Q36167512
Complications of biological therapy for inflammatory bowel diseasesQ36327680
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialQ37196938
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studyQ37600339
Management of severe ulcerative colitis: An up-to-dateQ40258181
Intravenous cyclosporin in ulcerative colitis: a five-year experienceQ41671378
Assessment of severity in colitis: a preliminary studyQ41988487
Changing referral patterns for surgical treatment of ulcerative colitisQ42058628
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.Q43085148
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitisQ43582796
Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral).Q43658939
Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitisQ44230091
Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitisQ44535154
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.Q46531976
Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysisQ48161573
P433issue6
P921main subjectcyclosporineQ367700
P304page(s)1291-1297
P577publication date2018-05-01
P1433published inInflammatory Bowel DiseasesQ15749161
P1476titleClinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy
P478volume24

Search more.